E. Ohman J or Asset Management AB Reduces Stock Position in Becton, Dickinson and Company $BDX

E. Ohman J or Asset Management AB cut its position in Becton, Dickinson and Company (NYSE:BDX) by 41.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,106 shares of the medical instruments supplier’s stock after selling 5,094 shares during the period. E. Ohman J or Asset Management AB’s holdings in Becton, Dickinson and Company were worth $1,379,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BDX. Focus Financial Network Inc. boosted its position in Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock valued at $504,000 after buying an additional 58 shares during the last quarter. Phillips Wealth Planners LLC raised its position in Becton, Dickinson and Company by 2.7% during the 3rd quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after buying an additional 58 shares during the last quarter. Union Bancaire Privee UBP SA lifted its stake in Becton, Dickinson and Company by 25.7% during the 4th quarter. Union Bancaire Privee UBP SA now owns 289 shares of the medical instruments supplier’s stock valued at $56,000 after acquiring an additional 59 shares during the period. CX Institutional lifted its stake in Becton, Dickinson and Company by 3.6% during the 3rd quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock valued at $324,000 after acquiring an additional 60 shares during the period. Finally, KCM Investment Advisors LLC boosted its holdings in shares of Becton, Dickinson and Company by 4.1% in the 3rd quarter. KCM Investment Advisors LLC now owns 1,525 shares of the medical instruments supplier’s stock valued at $285,000 after acquiring an additional 60 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2%

BDX opened at $155.89 on Wednesday. The company has a market cap of $44.39 billion, a PE ratio of 25.43, a price-to-earnings-growth ratio of 11.33 and a beta of 0.24. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a 50-day moving average price of $183.69 and a 200 day moving average price of $188.31. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the previous year, the firm posted $3.43 EPS. Becton, Dickinson and Company’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has authorized a share buyback program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of analysts have recently weighed in on BDX shares. Bank of America increased their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Wells Fargo & Company lowered their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 10th. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Finally, TD Cowen boosted their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $191.62.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 2,787 shares of company stock valued at $551,391. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.